An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer

A Multi-center Observational Study of Bevacizumab Plus 5-FU Based Chemotherapy as First Line and Second Line Treatment for Chinese Patients With Metastatic Colorectal Cancer (ML25391)

This observational study will evaluate the safety and efficacy of Bevacizumab in combination with 5-Fluorouracil based chemotherapy as first-line and second-line therapy in Chinese participants with metastatic colorectal cancer. Data will be collected from each participant for up to 3 years.

Inclusion Criteria:

• Adult Chinese participants, >/= 18 years of age
• Histologically confirmed and previously untreated metastatic colorectal cancer
• Initiated on treatment with Bevacizumab (in combination with 5-FU based chemotherapy) according to locally approved Bevacizumab China package insert
• Documented participant with medical records

Exclusion Criteria:

• Recent history of serious hemorrhage or hemoptysis of >/= 1/2 teaspoon of red blood
• Proteinuria at baseline (>/=2 grams / 24 hours)
• Major surgical procedure within 28 days prior to study treatment start, not fully healed wounds
• Pregnant or lactating women